CGP-37849

CGP-37849 is a drug that acts as a competitive antagonist at the NMDA receptor. It is a potent and selective blocker of the excitatory amino acid receptor subtype, and has neuroprotective effects. It has been used in scientific research to study the function of the NMDA receptor and its role in conditions such as schizophrenia, Alzheimer's disease, and neuropathic pain.

Pharmacology[edit | edit source]

CGP-37849 acts as a competitive antagonist at the NMDA receptor, a type of ionotropic glutamate receptor. This means it binds to the same site on the receptor as the natural ligand, glutamate, and prevents it from activating the receptor. This action is thought to underlie its neuroprotective effects, as overactivation of the NMDA receptor can lead to neurotoxicity.

Uses in Research[edit | edit source]

Due to its potent and selective action at the NMDA receptor, CGP-37849 has been used in scientific research to study the function of this receptor and its role in various neurological and psychiatric conditions. For example, it has been used in studies investigating the role of the NMDA receptor in schizophrenia, a psychiatric disorder characterized by hallucinations, delusions, and cognitive impairment. It has also been used in research on Alzheimer's disease, a neurodegenerative disorder characterized by progressive memory loss and cognitive decline. In addition, it has been used in studies on neuropathic pain, a type of chronic pain caused by damage to the nervous system.

See Also[edit | edit source]

CGP-37849 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.